<DOC>
	<DOC>NCT02884726</DOC>
	<brief_summary>The purpose of this study is to assess the safety and tolerability of Mesothelin-ADC in subjects with advanced and/or metastatic solid tumors.</brief_summary>
	<brief_title>Phase 1 Study of Mesothelin-ADC</brief_title>
	<detailed_description />
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Must have histological confirmation of advanced and/or metastatic solid tumors which are expected to express mesothelin Must have received and either progressed or been intolerant to the standard treatment regimen in the advanced or metastatic setting, if such a therapy exists Must have measurable tumor per Response Evaluation Criteria in Solid Tumors (RECIST) or modified RECIST for malignant pleural mesothelioma Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 Cancer metastases in the brain Uncontrolled or significant cardiovascular disease Moderate eye disorders Moderate peripheral neuropathy Known past or active hepatitis B or C infection Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>